In vivo antitumor activity of NKT cells activated by the combination of IL-12 and IL-18.
Interleukin-12 and IL-18 have been demonstrated to potentiate innate immunity in a variety of experimental tumor models, but the functional roles of NK and/or NKT cells and their mechanism of action in these models have not been fully addressed. Through adoptive transfer of NKT cells activated in vitro with a combination of IL-12 plus IL-18 (IL-12/IL-18 NKT) into syngeneic animals, we demonstrate in this study that IL-12/IL-18 NKT cells are essential and collaborate with the host's own NK cells in natural host immunity against the growth of ALC and MC57X syngeneic tumors. The relative roles of the adoptively transferred IL-12/IL-18 NKT cells and endogenous NK cells in host protection were first shown in normal C57BL/6 (B6) mice treated with anti-asialo GM1 Ab that selectively depletes NK cells; second, in B6.TCRJalpha281(-/-) mice specifically deficient for NKT cells; and third, in B6.scid mice that also lack NKT cells. Furthermore, by injecting normal B6 mice with anti-IL-2 and/or anti-IFN-gamma mAb, we could demonstrate that effective innate immunity against both types of syngeneic tumors was dependent on the production of IL-2 and IFN-gamma by the adoptively transferred NKT cells. In vitro studies confirmed both the secretion of IL-2 and IFN-gamma by the IL-12/IL-18-activated NKT cells and their collaborative role with NK cells for lysis of ALC and MC57X syngeneic tumor targets. This is the first description of an antitumor function of IL-12/IL-18 NKT cells adoptively transferred into syngeneic hosts that provides the basis for a new modality in the cellular immunotherapy of cancer.
Baxevanis
Constantin N
CN
Cancer Immunology and Immunotherapy Center, St. Savas Hospital, Athens, Greece. baxevani@ath.forthnet.gr
Gritzapis
Angelos D
AD
Papamichail
Michael
M
D019264:Adoptive Transfer; D000818:Animals; D000941:Antigens / Q000096:biosynthesis; D000954:Antigens, Surface; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000494:pharmacology; D017252:CD3 Complex / Q000096:biosynthesis; D045744:Cell Line, Tumor; D002478:Cells, Cultured; D003602:Cytotoxicity, Immunologic; D005354:Fibrosarcoma / Q000473:pathology / Q000517:prevention & control*; D006131:Growth Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D007371:Interferon-gamma / Q000096:biosynthesis / Q000502:physiology; D018664:Interleukin-12 / Q000008:administration & dosage / Q000494:pharmacology; D020382:Interleukin-18 / Q000008:administration & dosage / Q000494:pharmacology; D007376:Interleukin-2 / Q000096:biosynthesis / Q000502:physiology; D007694:Killer Cells, Natural / Q000276:immunology* / Q000378:metabolism / Q000637:transplantation; D037181:Lectins, C-Type; D008213:Lymphocyte Activation / Q000276:immunology*; D016399:Lymphoma, T-Cell / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D051379:Mice; D008810:Mice, Inbred C57BL; D016513:Mice, SCID; D055651:NK Cell Lectin-Like Receptor Subfamily B; D009368:Neoplasm Transplantation; D014176:Protein Biosynthesis; D011506:Proteins; D016176:T-Lymphocyte Subsets / Q000276:immunology* / Q000378:metabolism / Q000637:transplantation
D000941:Antigens; D000954:Antigens, Surface; D017252:CD3 Complex; D006131:Growth Inhibitors; D020382:Interleukin-18; D007376:Interleukin-2; D037181:Lectins, C-Type; D055651:NK Cell Lectin-Like Receptor Subfamily B; D011506:Proteins; D018664:Interleukin-12; D007371:Interferon-gamma